bioRxiv Science⌕ Search

Biology subjects

Boeken, D.

Publications and source records attributed to Boeken, D..

3 recordsLinked to original sources

Rare bioactive tau oligomers from Alzheimer brain support both templated misfolding and fibril formation

In Alzheimers disease, both classical neurofibrillary tangles, and diffusible, aqueous soluble (High Molecular Weight, or HMW) species are able to support templated misfolding. How these tau proteoforms relate is uncertain. Using sequential size exclusion and anion exchange chromatography, we fractionated the HMW tau population and found both seed competent, and seed not competent proteoforms. Super resolution, atomic force, and immunogold electron microscopy confirmed that the size and conformation of both bioactive and non-bioactive tau proteoforms are similar, with dimers, trimers, and tetramers predominating. The presence of surface phosphorylation correlates with seeding capacity. Bioactive tau at fMol concentrations can induce seeding in a reporter cell. The soluble bioactive species support aggregation of a truncated repeat domain tau construct into thioflavin T positive fibrils and retain seeding activity over serial amplification in vitro and in cellulo, whereas non-bioactive oligomeric species do not. Together, these findings indicate that oligomeric assembly is required but not sufficient for seeding; instead, specific biochemical attributes of a rare oligomeric tau subset confer self-propagating, prion-like templated misfolding.

neuroscience↗

Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab

Monoclonal antibodies Aducanumab, Lecanemab, Gantenerumab, and Donanemab have been developed for treatment of Alzheimers disease. Here, we have used single-molecule detection techniques and super-resolution imaging to characterise the binding of these antibodies to beta-amyloid aggregates including human post-mortem brain samples. Lecanemab is the best antibody in terms of binding to the small-soluble beta-amyloid aggregates, affinity, aggregate coating, and the ability to bind to post-translationally modified species, explaining its therapeutic success.

neuroscience↗

A human neuronal model of sporadic Alzheimer's disease induced by FBXO2 downregulation shows A β aggregation, tau hyperphosphorylation and functional network impairment

Sporadic Alzheimers disease (sAD) arises from a complex interplay between genetic and environmental factors that remains poorly understood, making it challenging to develop accurate cell models. To address this problem, by hypothesing that the early disease sAD states can be characterised by transcriptomic fingerprints, we assessed the effect on A{beta} aggregation in human neuroblastoma cells a set of genes obtained by analysing snRNA-seq data from post-mortem AD patients. We then validated the most effective genes in human iPSC-derived cortical neurons, and selected FBXO2, a gene encoding a subunit of the ubiquitin protein ligase complex SCF, for further analysis. We found that early downregulation of FBXO2 in human iPSC-derived cortical neurons resulted in A{beta} aggregation, tau hyperphosphorylation, and structural and functional neuronal network impairment. Based on these results, we report a neuronal sAD model (FBXO2 KD sAD) that recapitulates a set of molecular hallmarks of sAD. We suggest that this strategy can be expanded towards the generation of panels of preclinical stem cell-derived models that recapitulate the molecular complexity of the broad spectrum of AD patients.

neuroscience↗